A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Latest Information Update: 16 Jan 2024
At a glance
- Drugs 611-3SBio (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Sponsors Sunshine Guojian Pharmaceutical
- 10 Jan 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 22 May 2023 New trial record